Patent application number | Description | Published |
20090047293 | Compositions Comprising Yersinia Pestis Antigens - Disclosed are several | 02-19-2009 |
20110052620 | HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH | 03-03-2011 |
20120066779 | HEPATITIS C RECEPTOR PROTEIN CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes. | 03-15-2012 |
20120070456 | POLYPEPTIDE CARRIER PROTEIN - The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years. | 03-22-2012 |
20120088685 | DIAGNOSIS OF NEUROPSYCHIATRIC AND BEHAVIOURAL DISORDERS - This invention provides a method of identifying GAS infection as the cause of a neuropsychiatric or behavioural disorder in a patient, or of identifying a patient at risk of developing a neuropsychiatric or behavioural disorder caused by GAS infection. This invention also provides associated protein arrays. | 04-12-2012 |
20120093850 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Hla polypeptides having various deletions, insertions, and/or mutations which are useful for immunisation are provided herein. Also provided herein are Hla heptamers which are non-haemolytic. Additionally, an effective | 04-19-2012 |
20120093851 | CHLAMYDIA ANTIGENS - The invention provides | 04-19-2012 |
20120107340 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 05-03-2012 |
20130195907 | OMV VACCINES - The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of | 08-01-2013 |
20130273091 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof. | 10-17-2013 |
20140093510 | CHLAMYDIA ANTIGENS - The invention provides | 04-03-2014 |
20140178425 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 06-26-2014 |
20150079124 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-19-2015 |
20150086582 | NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS - The invention provides proteins from | 03-26-2015 |